A novel liquid biopsy has proven to be accurate, sensitive and specific in diagnosing the presence and severity of nonalcoholic steatohepatitis/liver fibrosis and is more reliable than currently used biomarkers, according to a recent study.
To address the need for noninvasive biomarkers for diagnosing NASH and monitoring disease progression and treatment response, a research team from Italy conducted a multicenter study of patients with histologically proven nonalcoholic fatty liver disease or